LIST OF IN-TEXT TABLES
Table 1. Historical Responses in Refractory NHL (SD or PD to Last Line of Therapy) .....................22 Table 2. Bridging Therapy Regimens...................................................................................................38 6 - a 6 2 Table 3. Debulking Therapy Regimens ................................................................................................39 Table 4. Incidence of DLT and Response among Subjects with B-cell Lymphomas and Dosed with Group 2 and Group 3 Conditioning Chemotherapy and ≤ 2.5 x 10antiCD19 CAR T Cells.................................................................................................................46 Table 5. DLTEvents among Subjects with B-cell Lymphomas and Dosed with ≤ 1-2.0 x 10anti-CD19 CAR T Cells and Cyclosphosphamide 30 mg/kg x 2 Days-Fludarabine 25 mg/mx 5 Days .................................................................................................................46 Table 6. Tocilizumab and Corticosteroids Use in ZUMA-1 Phase 2 Pivotal Study Primary Analysis ..................................................................................................................................48 Table 7. Rates of Neurologic Toxicities and CRS in the Phase 1 and 2 Pivotal Study versus Phase 2 Safety Management Study Cohort 3 .........................................................................49 Table 8. Grading and Management of CRS in Cohort 4 and Cohort 6 .................................................53 Table 9. Grading and Management of Neurologic Toxicities in Cohort 4 and Cohort 6......................55 Table 10. Management of Cerebral Edema in Cohort 4 and Cohort 6 ...................................................57 Table 11. Schedule of Assessments........................................................................................................80 Table 12. Schedule of Assessments (Long-term Follow-up Period) ......................................................83